Bausch + Lomb said on Thursday its glaucoma eye drop had missed ​the main goal in a mid-stage ‌trial of replicating visual function improvements observed in a smaller study.

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating ...

A surprising discovery is reshaping scientists' understanding of how humans develop sharp central vision before birth.

Because the Greenland shark lives in the dim depths of the ocean and is often infested with parasites that attach to its eyes ...

Scientists have found out how a person develops acute central vision before birth. It turned out that the interaction of a ...

, July 9 -- Scientists have discovered how the human eye develops sharp central vision before birth, a finding that could pave the way for new treatments to restore sight in people with serious eye ...

A baby born on July 4, 2026, America’s 250th anniversary, in Danville — Giovanni Young. The Georgetown Fair starts on ...

RICHMOND HILL, N.Y.-- (BUSINESS WIRE)--Jul 8, 2026-- ...

Drivers aged 70 and over could be required to pass four separate eyesight tests to keep their driving licence under proposals ...

Sera Prognostics Inc., The Pregnancy Company® , focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup ...

Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") today announced new research insights at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, ...